BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin M, Holmes F, Moy B, Mansi J, Gnant M, Buyse M, Barrios C, Bryce R, Wong A, Chan A. Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial. The Breast 2021;56:S19. [DOI: 10.1016/s0960-9776(21)00093-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]